Jane Street
CLDI icon

Jane Street’s Calidi Biotherapeutics CLDI Stock Holding History

Jane Street’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.23K Buy
3,392
+1,217
+56% +$3.93K ﹤0.01% 11312
2026
Q1 		$8.31K Buy
2,175
+1,457
+203% +$17.5K ﹤0.01% 11319
2025
Q4 		$13.4K Buy
+718
New +$16.9K ﹤0.01% 10796
2025
Q1 		– Sell
-174
Closed -$38.5K – 9550
2024
Q4 		$38.5K Buy
+174
New +$52.2K ﹤0.01% 9036

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jane Street's CLDI Position: Q2 2026 in Review

Jane Street increased its Calidi Biotherapeutics (CLDI) stake by 56% in Q2 2026, buying an estimated $3.93K and bringing the position to 3,392 shares worth $9.23K. The position accounts for ﹤0.01% of the portfolio, ranked #11312.

Jane Street first reported a position in CLDI in Q4 2024 and has held it in 4 quarters since. The position peaked at $38.5K in Q4 2024. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Jane Street held 3,392 shares of Calidi Biotherapeutics worth $9.23K as of Q2 2026.
  • Jane Street bought 1,217 Calidi Biotherapeutics shares in Q2 2026, an estimated $3.93K.
  • Calidi Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #11312 holding.
  • Jane Street first reported a position in Calidi Biotherapeutics in Q4 2024 and has held it in 4 quarters since.
  • Jane Street's Calidi Biotherapeutics position peaked at $38.5K in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.